Evaluating coronary heart disease risk: Tiles in the mosaic

JAMA

Volumn 277, Issue 17, 1997, Pages 1387-1390

  Hoeg, Jeffrey M ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; GENETIC SUSCEPTIBILITY; HEART DISEASE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031002172     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.17.1387     Document Type: Article

References (43)

1. Wissler RW, PDA Collaborating Investigators. New insights into the pathogenesis of atherosclerosis as revealed by PDA. Atherosclerosis. 1994; 108(suppl):S3-S20.
2. Singh GK, Mathews TJ, Clarke SC, Yannicos T, Smith BL. Annual summary of births, marriages, divorces, and deaths; United States, 1994. Mon Vital Stat Rep. 1995;43:1-37.
3. Beadle GW, Tatum EL. Genetic control of biochemical reactions in neurospora. Proc Natl Acad Sci U S A. 1941;27:499-506.
4. Garrod AE. Inborn Factors in Disease. New York, NY: Oxford University Press; 1989:248.
5. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease six-year follow-up experience. Ann Intern Med. 1961;55:33-50.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
7. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
8. The Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg/day estrogen group. JAMA. 1973;226:652-657.
9. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. J Med. 1987; 317:1237-1245.
10. Scandinavian Simvastin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
11. Byington RP, Furberg CD, Crouse JR III, Espeland MA, Bond MG. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLCA-II). Am J Cardiol. 1995;76:54C-59C.
12. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
13. Cabin HS, Roberts WC. Quantification of amounts of coronary arterial narrowing in patients with types II and IV hyperlipoproteinemia and in those with known normal lipoprotein patterns. Am Heart J. 1981;101:52-58.
14. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. Circulation. 1995;92:1355-1374.
15. Hong MK, Mintz GS, Popma JJ, et al. Limitations of angiography for analyzing coronary atherosclerosis progression or regression. Ann Intern Med. 1994;121:348-354.
16. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
17. Keren G, Leon MB. Intravascular ultrasound of atherosclerotic vessels: changes observed during interventional procedures. Am J Cardiac Imag. 1994;8:129-139.
18. Matar FA, Mintz GS, Douek P, et al. Coronary artery lumen volume measurement using three-dimensional intravascular ultrasound: validation of a new technique. Cathet Cardiovasc Diagn. 1994; 33:214-220.
19. Amarenco P, Heinzlef O, Lucas C, et al, for the French Study of Aortic Plaques in Stroke Group. Atherosclerosis disease of the aortic arch as a risk factor for recurrent ischemic stroke. N Engl J Med. 1996;334:1216-1221.
20. Walsh BW, Sacks FM. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest. 1993;91:2126-2132.
21. Toussaint J-F, Southern JF, Fuster V, Kantor HL. T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1533-1542.
22. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte J Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15:827-832.
23. Lenk T. Rontgendiagnose der koronarsklerose in vivo. Fortschr Geb Rontgenstr. 1927;35:1265-1268.
24. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerosis lesions. J Clin Invest. 1993;91:1800-1809.
25. Demer LL, Watson KE, Boström K. Mechanism of calcification in atherosclerosis. Trends Cardiovasc Med. 1994;4:45-49.
26. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast CT in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb. 1994;14:1066-1074.
27. Guerci AD, Spadaro LA, Popma JJ, et al. Relation of coronary calcium score by electron beam computed tomography to arteriographic findings in asymptomatic and symptomatic adults. Am J Cardiol. 1997;79:128-133.
28. Rumberger JA, Schwartz RS, Simons DB, Sheedy PF III, Edwards WD, Fitzpatrick LA. Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. Am J Cardiol. 1994;74: 1169-1173.
29. Kajinami K, Takekoshi N, Mabushi H. Comparative merits of electron beam computed tomography when coronary atherosclerosis is suspected. Cardiol Rev. 1996;13:34-38.
30. Arad Y, Spadaro LA, Goodman K, et al. Predictive value of electron beam computed tomography of the coronary arteries: 19-month follow-up of 1173 asymptomatic subjects. Circulation. 1996;93: 1951-1953.
31. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, 1: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-774.
32. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
33. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265: 3255-3264.
34. Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 1992;85:2025-2033.
35. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary heart disease. Ann Intern Med. 1994;120:1012-1025.
36. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem. 1992; 38:793-797.
37. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
38. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386-389.
39. Steinberg D. Role of oxidized LDL and antioxidants in atherosclerosis. Adv Exp Med Biol. 1995;369:3948.
40. Hoeg JM, Santamarina-Fojo S, Berard AM, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A. 1996; 93:11448-11453.
41. Kashyap VS, Santamarina-Fojo S, Brown DR, et al. Apolipoprotein E deficiency in mice: gene replacement and prevention of atherosclerosis using adeno-virus vectors. J Clin Invest. 1995;69:1612-1620.
42. Linton MF, Atkinson JB, Fazio S. Prevention of atherosclerosis in apolipoprotein E deficient mice by bone marrow transplantation. Science. 1995;267: 1034-1037.
43. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.